Multiple sclerosis patients with severe walking disability have clinically meaningful improvements in walking speed with prolonged-release fampridine

被引：0
|
作者：
Hartung, H. P.
Goodman, A.
Putzki, N.
机构：
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [31] Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2012, 28 (12) : 1 - 4
  • [32] Relationship between Heat Intolerance and Response to Prolonged-Release Fampridine in Patients with Multiple Sclerosis
    Ziemssen, Tjalf
    Berger, Thomas
    Potts, James
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [33] TREATMENT COSTS AND PATTERNS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE IN GERMANY
    Lee, A.
    Liu, Y.
    Gleissner, E.
    Prosser, C.
    Kinter, E.
    Landsman-Blumberg, P.
    Braun, S.
    VALUE IN HEALTH, 2015, 18 (07) : A753 - A753
  • [34] A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis
    Ramio-Torrenta, L.
    Alvarez-Cermeno, J. C.
    Arroyo, R.
    Casanova-Estruch, B.
    Fernandez, O.
    Garcia-Merino, J. A.
    Hernandez, M. A.
    Izquierdo, G.
    Martinez-Yelamos, S.
    Meca, J.
    Moral, E.
    Olascoaga, J.
    Prieto, J. M.
    Saiz, A.
    NEUROLOGIA, 2018, 33 (05): : 327 - 337
  • [35] Effectiveness of Functional Electrical Stimulation on Walking Speed, Functional Walking Category, and Clinically Meaningful Changes for People With Multiple Sclerosis
    Street, Tamsyn
    Taylor, Paul
    Swain, Ian
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2015, 96 (04): : 667 - 672
  • [36] Multiple Sclerosis Walking Scale (MSWS-12): exactly what clinical benefits do prolonged-release fampridine responders actually get?
    Hobart, J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S319 - S320
  • [37] Do Cerebellar Symptoms Predict Treatment Response to Prolonged-Release Fampridine in Multiple Sclerosis Patients?
    Siva, Aksel
    Limmroth, Volker
    Potts, James
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [38] Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis
    Weller, D.
    Lorincz, L.
    Sutter, T.
    Reuter, K.
    Linnebank, M.
    Weller, M.
    Zorner, B.
    Filli, L.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 416
  • [39] Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis
    Fernandez, Oscar
    Berger, Thomas
    Hartung, Hans-Peter
    Putzki, Norman
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (06) : 649 - 665
  • [40] Treatment patterns and costs among patients with multiple sclerosis treated with prolonged-release fampridine in Germany
    Lee, A.
    Liu, Y.
    Gleissner, E.
    Prosser, C.
    Kinter, E.
    Landsman-Blumberg, P.
    Braun, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 670 - 670
12345